Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erenumab Phase 2 in Japanese Episodic Migraine
NCT02630459Phase 2Completed
- Sponsor
- Amgen
- Start
- Jan 2016
- Primary completion
- Sep 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of erenumab in migraine, sponsored by Amgen. Started Jan 2016; status: completed.
02
Drugs
erenumab
03
Conditions
migraine
Beyond the preview
Go deeper on NCT02630459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02630459.